

Nã°ria GuaÃ±abens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5795559/publications.pdf>

Version: 2024-02-01

80
papers

3,646
citations

117625

34
h-index

133252

59
g-index

87
all docs

87
docs citations

87
times ranked

3204
citing authors

#	ARTICLE	IF	CITATIONS
1	Position of the Spanish Society of Rheumatology (SER) and the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) on romosozumab. <i>ReumatologÃ±a ClÃ±nica</i> (English Edition), 2022, , .	0.3	0
2	Bilirubin increases viability and decreases osteoclast apoptosis contributing to osteoporosis in advanced liver diseases. <i>Bone</i> , 2022, 162, 116483.	2.9	8
3	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281.	3.6	132
4	Bisphosphonates in inflammatory rheumatic diseases. <i>Bone</i> , 2021, 146, 115887.	2.9	9
5	Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study. <i>Osteoporosis International</i> , 2021, 32, 1333-1342.	3.1	12
6	Posicionamiento de la Sociedad EspaÃ±ola de ReumatologÃ±a (SER) y la Sociedad EspaÃ±ola de InvestigaciÃ³n Ã±sea y Metabolismo Mineral (SEIOMM) respecto a romosozumab. <i>ReumatologÃ±a ClÃ±nica</i> , 2021, , .	0.5	0
7	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.	1.9	47
8	Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases. <i>Gene</i> , 2020, 725, 144167.	2.2	17
9	Fusion of sacroiliac joints in acromegaly: a challenging finding. <i>Rheumatology</i> , 2020, 59, 898-898.	1.9	1
10	Response to: Some Questions About the Article â€œThe Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Reportâ€. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 212-213.	2.8	0
11	Imaging Follow-up of SAPHO Syndrome Treated With Zoledronic Acid. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e155-e157.	0.9	2
12	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1682-1699.	3.6	53
13	Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestaticâ€induced osteoporosis. <i>Liver International</i> , 2020, 40, 2767-2775.	3.9	13
14	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	3.8	5
15	Characteristics of Early Paget's Disease in <sc><i>SQSTM1</i></sc> Mutation Carriers: Baseline Analysis of the <sc>ZIPP</sc> Study Cohort. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1246-1252.	2.8	12
16	Balancing benefits and risks in the era of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1988397.	2.7	10
17	Clinical Guidelines on Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2327-2329.	2.8	43
18	The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 3-21.	2.8	83

#	ARTICLE	IF	CITATIONS
19	Response Letter to the Editorâ€”Diamond et al, <i>JBMR</i>. Journal of Bone and Mineral Research, 2019, 34, 1185-1186.	2.8	2
20	Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone. Bone, 2019, 124, 132-136.	2.9	5
21	The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. Endocrine, 2019, 64, 441-455.	2.3	22
22	Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. Journal of Bone and Mineral Research, 2019, 34, 579-604.	2.8	102
23	Incidence of Mutations in the <i>ALPL</i>, <i>GGPS1</i>, and <i>CYP1A1</i> Genes in Patients With Atypical Femoral Fractures. JBMR Plus, 2019, 3, 29-36.	2.7	23
24	Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. Seminars in Arthritis and Rheumatism, 2019, 49, 197-203.	3.4	21
25	FRIO487â€…UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .		2
26	FRIO466â€…RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .		0
27	Zoledronate in the prevention of Pagetâ€™s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to preventSQSTM1-mediated Pagetâ€™s disease of bone. BMJ Open, 2019, 9, e030689.	1.9	15
28	Osteoporosis in chronic liver disease. Liver International, 2018, 38, 776-785.	3.9	79
29	Identification of hypophosphatasia in a clinical setting: Clinical manifestations and diagnostic recommendations in adult patients. Medicina ClÃnica (English Edition), 2018, 150, 75-79.	0.2	1
30	Significado clÃnico del aumento de los valores sÃ©ricos de FGF-23 en la displasia fibrosa. Medicina ClÃnica, 2018, 151, 65-67.	0.6	2
31	Uncommon local reaction at the injection site of subcutaneous methotrexate. Rheumatology, 2018, 57, 27-27.	1.9	9
32	IdentificaciÃ³n de hipofosfatasa en la prÃ¡ctica clÃnica: manifestaciones clÃnicas y recomendaciones diagnÃsticas en pacientes adultos. Medicina ClÃnica, 2018, 150, 75-79.	0.6	6
33	Primary biliary cholangitis and bone disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 63-70.	2.4	13
34	Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2017, 32, 1935-1944.	2.8	35
35	Concordance between direct and indirect measurements of free 25-OH vitamin D. Clinica Chimica Acta, 2017, 475, 169-171.	1.1	9
36	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 2017, 105, 11-17.	2.9	373

#	ARTICLE	IF	CITATIONS
37	Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus. Journal of Bone and Mineral Research, 2016, 31, 1774-1782.	2.8	3
38	Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis. Journal of Bone and Mineral Research, 2016, 31, 1725-1733.	2.8	27
39	Displasia fibrosa. Revisi3n cl�nica y abordaje terap�utico. Medicina Cl�nica, 2016, 147, 547-553.	0.6	19
40	Reference intervals for bone turnover markers in Spanish premenopausal women. Clinical Chemistry and Laboratory Medicine, 2016, 54, 293-303.	2.3	26
41	Invasive Mycobacterium marinum infection. Joint Bone Spine, 2015, 82, 462.	1.6	1
42	Bone Turnover Markers: A Clinical Review. Clinical Reviews in Bone and Mineral Metabolism, 2015, 13, 83-97.	0.8	6
43	Effect of Recent Spinal Cord Injury on Wnt Signaling Antagonists (Sclerostin and Dkk-1) and Their Relationship With Bone Loss. A 12-Month Prospective Study. Journal of Bone and Mineral Research, 2015, 30, 1014-1021.	2.8	29
44	Bone Disease in Patients with Cirrhosis. , 2015, , 295-305.		0
45	Inflammatory arthropathy of the manubriosternal joint. Rheumatology, 2014, 53, 1731-1731.	1.9	1
46	Calcific Periarthritis as the Only Clinical Manifestation of Hypophosphatasia in Middle-Aged Sisters. Journal of Bone and Mineral Research, 2014, 29, 929-934.	2.8	64
47	Ursodeoxycholic acid decreases bilirubin�induced osteoblast apoptosis. European Journal of Clinical Investigation, 2014, 44, 1206-1214.	3.4	26
48	The Role of Wnt Signaling and Sclerostin in the Pathogenesis of Glucocorticoid-Induced Osteoporosis. Current Osteoporosis Reports, 2014, 12, 90-97.	3.6	57
49	Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology, 2013, 58, 2070-2078.	7.3	81
50	Bone Disease in Patients Awaiting Liver Transplantation. Has the Situation Improved in the Last Two Decades?. Calcified Tissue International, 2013, 93, 571-576.	3.1	19
51	Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver International, 2013, 33, 1029-1038.	3.9	27
52	25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone, 2012, 51, 54-58.	2.9	67
53	Implications of a New Radiological Approach for the Assessment of Paget Disease. Calcified Tissue International, 2012, 91, 409-415.	3.1	15
54	Management of osteoporosis in liver disease. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 438-445.	1.5	44

#	ARTICLE	IF	CITATIONS
55	Osteomalacia revisited. <i>Clinical Rheumatology</i> , 2011, 30, 639-645.	2.2	52
56	Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. <i>Hepatology</i> , 2011, 54, 2104-2113.	7.3	61
57	Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1â€“34)] in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 503-511.	2.8	291
58	Search for hidden secondary causes in postmenopausal women with osteoporosis. <i>Menopause</i> , 2010, 17, 135-139.	2.0	37
59	Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2010, 138, 2348-2356.	1.3	115
60	Liver and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 84-94.	3.0	58
61	High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 347-354.	2.7	19
62	Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. <i>Transplant International</i> , 2009, 22, 198-206.	1.6	47
63	Prevalence of Paget's disease of bone in Spain. <i>Bone</i> , 2008, 43, 1006-1009.	2.9	38
64	Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment. <i>Clinics in Liver Disease</i> , 2008, 12, 407-424.	2.1	61
65	Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. <i>Liver International</i> , 2007, 27, 492-497.	3.9	27
66	Treatment of bone disorders in liver disease. <i>Journal of Hepatology</i> , 2006, 45, 445-453.	3.7	48
67	Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 311-315.	1.6	38
68	Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers. <i>Journal of Bone and Mineral Metabolism</i> , 2005, 23, 266-269.	2.7	23
69	Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, 573-577.	3.7	163
70	Non-Isomerized C-Telopeptide Fragments Are Highly Sensitive Markers for Monitoring Disease Activity and Treatment Efficacy in Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 588-595.	2.8	42
71	Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2268-2274.	0.4	96
72	Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy. <i>Archives of Internal Medicine</i> , 2003, 163, 789.	3.8	74

#	ARTICLE	IF	CITATIONS
73	Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy. Journal of Bone and Mineral Metabolism, 2002, 20, 116-120.	2.7	4
74	Collagen type IÎ±1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology, 2001, 33, 554-560.	7.3	64
75	Mutations in the gene encoding the latency-associated peptide of TGF-Î²1 cause Camurati-Engelmann disease. Nature Genetics, 2000, 26, 273-275.	21.4	205
76	Collagen-Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis. Journal of Bone and Mineral Research, 1998, 13, 731-738.	2.8	82
77	Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis and Rheumatism, 1997, 40, 461-468.	6.7	70
78	Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Journal of Bone and Mineral Research, 1995, 10, 458-465.	2.8	113
79	Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. Journal of Hepatology, 1994, 21, 24-28.	3.7	36
80	Sodium fluoride prevents bone loss in primary biliary cirrhosis. Journal of Hepatology, 1992, 15, 345-349.	3.7	67